An important one to keep in mind is that this could be a sign of an allergic reaction
Tirzepatide (10mg-30mg), Dual-Action Incretin Co-Agonist Engineered Engagement of GIP and GLP-1 Receptors Introduction Engineered Engagement of GIP and GLP-1 Receptors Tirzepatide is a 39-residue synthetic peptide engineered to simultaneously activate two distinct incretin receptors, the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), within a single molecular scaffold
Orforglipron Orforglipron, another oral GLP-1RA has being studied extensively for the management of T2DM and Obesity
With appropriate sequencing, glucose monitoring, and dose management, many researchers use both compounds without serious adverse events
Nonetheless, using insurance and Klinic's assistance in securing prior authorization, patients generally incur far lower expenses